You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5 Results
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
May 2022
Regimen
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Liposomal Daunorubicin and Liposomal Cytarabine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Dec 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC), based on criteria
Exceptional Access Program
    osimertinib - For the treatment of locally advanced, unresectable (stage III) non-squamous non-small cell lung cancer (NSCLC), based on criteria
Nov 2025